Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
12-week FF/VI versus tiotropium study on arterial stiffness in COPD
2010-024435-16Phase 3Completed
- Sponsor
- GSK
- Start
- Mar 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of fluticasone, vilanterol and tiotropium in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by GSK. Primary endpoint: Change from baseline in aortic pulse wave velocity. Started Mar 2011; status: completed.
02
Drugs
fluticasonevilanteroltiotropium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2010-024435-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024435-16.